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BACKGROUND: Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an
economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom.
METHODS: The study was based on a literature review and elicitation of expert opinion. The expert panel comprised 44 consultant
oncologists in NHS Hospital Trusts across England.
RESULTS: Ten first-line, 10 second-line and 12 third-line chemotherapy regimens were reported, reflecting wide variations in treatment
pathways. Predominant pathways emerged with: first-line treatment with oxaliplatin-based regimens, second-line treatment
with irinotecan-based regimens and third-line treatment with mitomycin-based regimens. Experts estimated the frequency of
febrile neutropaenia 8.4% (95% CI: 6.7–10.0), septic neutropaenia 4.7% (95% CI: 3.4–6.0) and severe diarrhoea 13.1% (95% CI:
10.8–15.5). Approaches for the clinical management of neutropaenia within the NHS were described.
CONCLUSIONS: This study identified wide variations in the clinical management of advanced CRC patients. Descriptions of current
treatment pathways are necessary for economic evaluations. Variations in clinical practice must be reflected in the model to ensure
the findings from an economic evaluation of UGT1A1 testing are sufficient to inform policy regarding the cost-effective use of NHS
resources.
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Irinotecan is a chemotherapeutic agent used in the treatment of
colorectal cancer (CRC) and lung cancer. In the United Kingdom,
irinotecan is licensed for first- and second-line chemotherapy for
advanced CRC patients (electronic Medicines Compendium, 2009).
The main dose-limiting toxicities from irinotecan chemotherapy
are severe neutropaenia and diarrhoea.
Irinotecan is a pro-drug that is activated into SN-38 in the liver,
and then converted by hepatic and extrahepatic UDP-glucurono-
syltransferase (UGT) enzymes into an inactive compound, SN-38G
(Rivory and Robert, 1995). UGT1A1 enzyme is the major isozyme
involved in this conversion (Nagar and Blanchard, 2006). In
Caucasian populations, UGT1A1*1 and UGT1A1*28 genetic
variants accounts for 98–99% of UGT1A1 polymorphisms
(Palomaki et al, 2009). Individuals homozygous for UGT1A1*28
have been found to have increased risk of irinotecan-induced
severe neutropaenia (Ando et al, 2000; Innocenti et al, 2004; Rouits
et al, 2004) and severe diarrhoea (Ando et al, 2000; Marcuello et al,
2004; Ferraldeschi et al, 2009).
UGT1A1 pharmacogenetic test is a genotyping assay that can
predict the risk of irinotecan-related neutropaenia and diarrhoea
by providing information on patients’ genotype, which can be used
to stratify patients into low-, intermediate- or high-risk groups,
defined in terms of the risk of severe neutropaenia or diarrhoea
(Palomaki et al, 2009). Some evidence suggests that the association
between UGT1A1*28 and haematological toxicity depends on the
irinotecan dose, with a higher risk of toxicity for UGT1A1*28
homozygous individuals on medium- or high-dose irinotecan
regimens (Hoskins et al, 2007). In the United States, the Food and
Drug Administration advised that irinotecan dosing should be
reduced for individuals homozygous for UGT1A1*28 allele (United
States Food and Drug Administration, 2005) but do not specify the
degree of dose reduction. A prospective study (Toffoli et al, 2006)
found that CRC patients homozygous for the UGT1A1*28 alleles
may have increased clinical benefit and tumour response to
irinotecan-based chemotherapy. This increased benefit was only
statistically significant for surrogate outcomes, which were
progressive disease and stable disease, and did not result in
significant overall survival advantage. A pharmacogenetic test that
provides information on UGT1A1*28 genetic variation may have a
role in individualising irinotecan dosing to reduce the incidence of
severe neutropaenia and diarrhoea, thereby improving the safety Received 18 March 2010; revised 1 June 2010; accepted 9 June 2010
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from randomised controlled trials to support the use of UGT1A1
testing to guide irinotecan dosing.
In the United States, the Invader assay was marketed to test for
UGT1A1 status, costing between USD$250 and $500 a test
(Anonymous, 2006). Since January 2009, UGT1A1 testing has been
offered by a UK NHS laboratory at a fee of d30 per test. The
acquisition cost of the test is only one of many factors driving the
costs associated with its use. Altered clinical pathways arising from
the use of the pharmacogenetic test may lead to additional NHS
resource use downstream, and therefore needs to be assessed
within the broader framework of health economic evaluation.
Some evidence suggests that managing severe neutropaenia and
diarrhoea is expensive, time consuming and labour intensive
(Hassett et al, 2006; Maroun et al, 2007). Using the UGT1A1 test
results to inform irinotecan dosing by stratifying patients into
different risk groups will impact upon clinical treatment decisions,
patient outcomes and NHS resources. In 2009, a House of Lords
report on genomic medicine highlighted that many genetic tests
are diffusing into practice without proper assessments of their
clinical utility or validity (House of Lords Science and Technology
Committee, 2009).
The economic evaluation framework enables assessment of an
intervention’s incremental clinical benefits and costs over existing
treatments. Sculpher et al (1997) recommended an iterative
approach to economic evaluation, with an assessment in the early
life of the intervention, and supplemented by further evaluations
as and when new evidence become available. Because the UGT1A1
test is a new potential addition to practice and the level of evidence
required to achieve regulatory approval for this type of technology
is low (Payne, 2009), current empirical evidence on its costs and
benefits in clinical practice is likely to be limited. To date, two
economic evaluations of using UGT1A1 testing to inform
irinotecan prescribing have been published (Obradovic et al,
2008; Gold et al, 2009). However, both studies were based on the
US health-care system and assumed irinotecan regimens and care
pathways that are not relevant to current UK practice.
The results of a UK relevant economic evaluation will aid
decision-makers commissioning health-care services to make an
informed decision on whether the UGT1A1 pharmacogenetic test
is a clinically and cost-effective use of scarce NHS resources.
Systematic evaluation of all relevant evidence within an economic
model will also allow explicit consideration of the expected value
of additional information generated by future research, for
example a prospective trial evaluating the clinical utility of
UGT1A1 test, and whether that would outweigh the cost
of undertaking the trial in the first place (Sculpher and
Claxton, 2005).
To construct the pathways for an economic model, it is
necessary to describe current clinical practice in the setting that
the UGT1A1 test will be used. This includes a description of
commonly used chemotherapy regimens, clinical management of
patients and incidence and management of adverse drug events
(ADEs). In general, there is a paucity of data describing current
clinical practice in UK cancer specialties, making evaluation of new
interventions challenging. The only previous study that described
clinical practice of advanced CRC specialties in the United
Kingdom (Seymour et al, 1997) found substantial diversity of
practice among experts in the field. At the time the study was
conducted, chemotherapy options within advanced CRC special-
ties were limited to 5-fluorouracil (5-FU)-based regimens.
An extensive selection of chemotherapy treatment options
available within current practice, accompanied by a rapidly
changing evidence base, result in wide variations in prescribing
practice and difficulties in describing current clinical practice in
terms of the main treatment pathways within oncology specialties.
The structure of the economic model must accurately reflect the
anticipated place of the new intervention in clinical practice.
This study aimed to inform an economic evaluation of UGT1A1
pharmacogenetic test by identifying the predominant advanced
CRC treatment pathways in the UK NHS, focusing specifically on
the composition and placement of commonly used irinotecan-
based regimens, the clinical management of patients on irinotecan-
based chemotherapy, the frequency of irinotecan-related diarrhoea
and neutropaenia, and the resource implications associated with
the management of patients experiencing irinotecan-related
neutropaenia. It also aimed to explore early perceptions about
the value of UGT1A1 pharmacogenetic testing in CRC specialties
by eliciting consultants’ current use and future preferences for the
test. The results from this study will inform an economic
evaluation of the UGT1A1 pharmacogenetic test, which will ensure
that the model design and subsequent results are relevant to
decision-makers in the NHS and are sufficient to inform policy
regarding the cost-effective use of NHS resources.
METHODS
Initially, systematic reviews of the literature were planned, using
electronic search strategies and methods described in The
Cochrane Handbook of Systematic Reviews (The Cochrane
Collaboration–Higgins and Green, 2009) to identify publications
that report the frequency of irinotecan-related neutropaenia and
diarrhoea, describe CRC chemotherapy treatment pathways and
describe clinical management of irinotecan-related neutropaenia
in the United Kingdom. Attempts at a comprehensive systematic
review based on terms relating to toxicity were hampered by
insurmountable difficulties in identifying relevant studies. Two
main problems were identified. First, key studies of irinotecan-
based regimens consist primarily of Phase III clinical trials that
cannot be identified by search terms that describe harm from
medicines such as ‘adverse reactions’ and ‘neutropaenia or
diarrhoea’. Second, attempts to identify studies other than Phase
III trials that report the frequency of irinotecan adverse events
yielded too many irrelevant publications but also missed key
studies because (i) of the many terms to describe harm from
medicines and (ii) these studies may not have these terms indexed
as keywords. It is well recognised that searches for adverse events
are problematic because data are often sparse with various
challenges in identifying relevant studies (Craig et al, 2009; The
Cochrane Collaboration–Higgins and Green, 2009).
The initial review also revealed a paucity of data describing
current NHS treatment pathways of CRC chemotherapy and
management of neutropaenia. No publications describing NHS
patients’ current clinical pathways were identified, because trial
protocol often dictates clinical practice. The limitations of using
this method meant that alternative methods were required to
identify the frequency of irinotecan’s adverse events and NHS
treatment pathways for the economic model.
Two methods were used in parallel: (1) a review of relevant
literature identified from a published systematic review and (2) a
national survey of expert opinion on current practice within NHS
CRC specialties. The study involved three steps. Step 1 identified
the range of potential chemotherapy regimens evaluated in
published randomised controlled trial (RCTs) for advanced CRC
(identified from the published systematic review). Step 2 used the
survey to identify current UK practice. Step 3 combined
the findings from the literature review and survey to select the
published trials relevant to UK practice.
Review of published RCTs
A published systematic review of chemotherapy treatment regi-
mens for advanced CRC (Golfinopoulos et al, 2007) was used to
identify publications reporting RCTs that used irinotecan-based
chemotherapy. The bibliography of this review was also searched
to identify additional studies.
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Elicitation of expert opinion was required to inform the economic
evaluation as other data sources were not available (Philips et al,
2006). As there are no national databases available to identify
oncology consultants with advanced CRC practice, a postal survey
method was developed to identify relevant clinical experts in CRC
specialties. The inclusion criteria for the survey were specific: an
eligible participant (an ‘expert’) was defined as a consultant
oncologist (specialist) who prescribes irinotecan to advanced CRC
patients in NHS Hospital Trusts in England. Publicly available
websites (Dr Foster and NHS Hospital Trusts) were used to
develop a sampling frame of potential clinical experts (n¼124).
This approach has previously been used to successfully identify
survey participants (Fargher et al, 2007; Wordsworth et al, 2008).
The survey questions were informed by discussions with clinical
and economic experts and literature review. The survey mainly
comprised closed-ended questions, supplemented with free-text
response options and was divided into two main sections:
(1) descriptions of advanced CRC treatment pathways and
irinotecan prescribing practice; and (2) current use and future
preferences for pharmacogenetic testing in CRC specialties (survey
available on request from corresponding author). The survey
results will be used to identify which of the published studies of
irinotecan-based regimens are relevant to UK practice.
After University of Manchester Ethics Committee approval and
a pilot study of eight consultant oncologists, the Pharmacogenetic
testing in Colorectal Cancer specialties survey was posted to
experts between May and August 2008. Clinicians were asked to
focus on NHS, rather than private, clinical practice when
answering the questions to reflect the same perspective as the
economic evaluation. After 1 month, a postal reminder was sent to
non-respondents and then a further 1 month later a random
sample of 33% of non-respondents was telephoned to identify their
reason(s) for not participating.
Analysis
Data on the frequencies of irinotecan-related neutropaenia and
diarrhoea that were identified in published RCTs found from the
hand search of the literature (the published systematic review and
the references) were tabulated. Survey data were summarised with
descriptive statistics using SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
Clinicians’ estimates were weighted against the number of
advanced CRC patients seen by them in 2007 as a proxy measure
to account for diverse levels of experience and expertise in CRC.
To be included in the weighted analysis, respondents must have
provided estimates for both the parameter of interest and number
of patients. For scale data where respondents indicated less than a
certain value (for example, o10%), the mean between zero and
that value was inputted for analysis purposes (for example, 5%). If
respondents provided data as a range value, then the mean of the
range was used. Estimates from the survey on the frequency of
ADEs in NHS practice were compared to the incidence data from
the identified trials.
RESULTS
Results are presented in two sections: (1) the findings from the
literature review and (2) the results of the national survey. It was
necessary to analyse the national survey to inform the final
selection of the RCTs relevant to UK practice.
Literature review of published RCTs
The literature search identified 22 RCTs investigating the use of
irinotecan in combination with 5-FU, all of which can be found in the
published systematic review (Golfinopoulos et al, 2007). Twelve trials
used irinotecan and bolus 5-FU regimens, whereas 10 used irinotecan
and infusional 5-FU. There are a number of different regimens for
irinotecan with infusional 5-FU, including AIO, irinotecan modified de
Gramont (IrMdG) and variations of the FOLFIRI regimen.
It was, therefore, necessary to use the findings from the national
survey to define the regimen that is relevant to UK practice, which
was irinotecan with infusional 5-FU according to the IrMdG
regimen as second-line therapy. Of the 10 RCTs that used
irinotecan and infusional 5-FU, only 1 (Seymour et al, 2007) used
IrMdG regimen. There were two other trials that used chemo-
therapy regimens similar to the UK IrMdG regimen, which was
FOLFIRI with high-dose infusional 5-FU (Tournigand et al, 2004;
Van Cutsem et al, 2009). The frequencies of irinotecan-related
neutropaenia and diarrhoea from the three trials are summarised
in Table 1. In addition, one non-randomised Phase II study
(Leonard et al, 2002) of IrMdG, which was a pilot study for the
FOCUS trial, was found.
All three RCTs reported the frequencies of irinotecan-related
grade 3 and 4 neutropaenia and diarrhoea as defined by standard
criteria (National Cancer Institute, 2006). Only two (Tournigand
et al, 2004; Van Cutsem et al, 2009) reported the frequency of
febrile neutropaenia. None reported the frequency of septic
neutropaenia. Febrile and septic neutropaenia differ in severity
and clinical management, thus consume different levels of
resources, which make their frequencies key parameters for the
economic model.
Elicitation of expert opinion by national survey
The final expert panel comprised 44 consultants: 28 clinical
oncologists and 16 medical oncologists. Figure 1 illustrates how the
Table 1 Frequency of irinotecan-related neutropaenia and diarrhoea occurring in clinical trials
Study (Country)
Seymour et al, 2007
(United Kingdom)
Tournigand et al, 2004
(France)
Van Cutsem et al, 2009
(Multinational trial)
Regimen IrMdG: irinotecan 180mgm
 2 (30min),
levofolinate 175mg (2h), 5-FU 400mgm
 2
(bolus) and 5-FU 2400mgm
 2 (46h)
FOLFIRI: L-LV 200 or
DL-LV 400mgm
 2 (2h),
irinotecan 180mgm
 2 (90min),
5-FU 400mgm
 2 (bolus) and
5-FU 2400–3000mgm
 2 (46h)
FOLFIRI: L-LV 200 or DL-LV
400mgm
 2 (2h), irinotecan
180mgm
 2 (30–90min),
5-FU 400mgm
 2 (bolus)
and 5-FU 2400mgm
 2 (46h)
Previous chemo None 5-FU None FOLFOX6 None
Adverse drug events Mean (%) Mean (%) Mean (%) Mean (%) Mean (%)
Neutropaenia (all grades) Not reported Not reported 76 (all grades) 60 (all grades) Not reported
Neutropaenia (G3 & G4) 19 (G3 & G4) 18 (G3 & G4) 15 (G3) and 9 (G4) 21 (G3) and 0 (G4) 25 (G3 & G4)
Febrile neutropaenia Not reported Not reported 0 (G1 & G2) and 7 (G3 & G4)0 (G1 & G2) and 1 (G3 & G4) 2 (G3 & G4)
Severe diarrhoea 12 (G3 & G4) 8 (G3 & G4) 9 (G3) and 5 (G4) 7 (G3) and 1 (G4) 11 (G3 & G4)
Abbreviations: 5-FU¼5-fluorouracil; IrMdG¼irinotecan modified de Gramont; LV¼leucovorin.
Chemotherapy treatment pathways for CRC
FH Shabaruddin et al
317
British Journal of Cancer (2010) 103(3), 315–323 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
seligibility of participants was determined and the final expert panel
numbers.
A total of 58 clinicians returned the survey but 14 of these were
excluded, as they did not manage CRC patients on irinotecan
chemotherapy. One-third of the 66 clinicians who did not return
the survey (n¼22) were randomly selected and contacted by
telephone. Of the 22 clinicians contacted, 12 did not treat patients
with CRC, which reflects inaccuracies on the public websites. This
left an active sample of 98 potential experts and gave a 45%
(n¼44) survey completion rate. There was at least one consultant
from each English NHS region and Strategic Health Authority. The
mean time since graduation from medical school was 24 years
(range: 7–41 years). The mean number of patients seen by each
clinician in 2007 was 135 (range: 15–600).
Indications for irinotecan-based regimens All 44 experts use
irinotecan-based chemotherapy for palliative treatment of ad-
vanced CRC. Only 12 (27%) reported using irinotecan-based
regimens as neoadjuvant chemotherapy for potentially resectable
cancer. The following data are based on irinotecan regimens used
as palliative treatment of advanced CRC.
Chemotherapy regimens for advanced CRC patients To identify
the main chemotherapy treatment pathways, we asked clinicians to
assign an estimated percentage reflecting the frequency of use for
first-, second- and third-line chemotherapy regimens. Ten first-
line, 10 second-line and 12 third-line chemotherapy regimens were
reported. Oxaliplatin (130mgm
 2) in combination with capecita-
bine (1000mgm
 2) was reported to be the most commonly used
first-line regimen, followed by OxMdG (oxaliplatin (85mgm
 2)
with infusional 5-FU according to MdG regimen). Irinotecan
regimens were reported to be most frequently used for second-line
chemotherapy, with a slight preference for IrMdG (irinotecan
(180mgm
 2) with infusional 5-FU according to MdG regimen),
over irinotecan monotherapy (350mgm
 2). For third-line treat-
ment, the survey results suggested a clear preference for using
mitomycin (7mgm
 2) with either intravenous (protracted infu-
sion 5-FU 300mgm
 2) or oral fluoropyrimidine formulation (e.g.,
capecitabine 1250mgm
 2). Table 2 presents the five most
commonly used chemotherapy regimens for first-, second- and
third-line treatment of advanced CRC.
Management of patients on irinotecan regimens Three areas of
managing patients on irinotecan regimens were explored: the
clinical setting for administration, indications for stopping
treatment and duration of treatment.
(a) Clinical setting for administration of irinotecan regimens:
irinotecan regimens were frequently administered in the day
case setting (mean 56%, weighted mean 61%), followed by
outpatient setting (mean 42%, weighted mean 36%) and
inpatient setting (mean 3%, weighted mean 3%). The average
time spent in an outpatient clinic was 3.3h (n¼25, range
2–8h, 95% confidence interval (CI) 2.7–3.8h, mean weighted
estimate: 3.5h).
(b) Indications for stopping irinotecan regimens: there are many
potential reasons for stopping chemotherapy, especially in the
palliative setting. The majority of respondents (93%) answered
these specific questions. The most common reason reported
for stopping irinotecan-based chemotherapy was lack of
therapeutic response (41%), followed by completion of the
specified duration of chemotherapy (25%) and tumour
progression despite chemotherapy (21%). When asked for
the least likely reasons for cessation of irinotecan-based
regimens, 32% of clinicians reported severe chemotherapy-
related toxicity, followed by deterioration in patient’s clinical
condition (27%).
(c) Time duration for irinotecan treatment: on average, clinicians
estimated that irinotecan treatment was given for 5.0 months
(n¼13, range 3–6 months, 95% CI 4.2–5.8 months, mean
weighted estimate: 5.3 months).
Frequency of ADEs due to irinotecan regimens The experts
estimated the percentages of their advanced CRC patients on
irinotecan-based regimens who develop these ADEs:
1. Uncomplicated neutropaenia (neutropaenia of any grade not
complicated by fever or infection)
2. febrile neutropaenia (neutropaenia complicated by fever
X38.51C without clinically or microbiologically documented
infection)
3. septic neutropaenia (neutropaenia with a clinically or micro-
biologically documented infection)
4. severe diarrhoea (grade 3 or 4 diarrhoea)
Table 3 presents the experts’ estimates on the frequency of ADEs.
Figure 2 illustrates the wide ranges of estimated values and
66 did not return the survey 54 non-respondents 
44 respondents 
Survey
sent to
124
potential
experts 
58 returned the survey 
14 consultants did not meet
inclusion criteria 
12 out of 22 consultants randomly
contacted did not meet inclusion 
Figure 1 Flow chart describing the sampling frame for the survey.
Table 2 Frequently used first-, second- and third-line chemotherapy
regimens for advanced colorectal cancer patients
Mean percentage of use
Chemotherapy regimen
First-line chemotherapy
Unweighted mean
a
(%)
Weighted mean
b
(%)
Capecitabine+oxaliplatin 37.5 41.4
Oxaliplatin+MdG 22.7 26.5
Capecitabine or UFT 24.3 17.6
FOLFOX 4.9 4.9
Irinotecan+MdG 3.8 4.5
Second-line
chemotherapy
Unweighted mean
c
(%)
Weighted mean
d
(%)
Irinotecan+MdG 23.2 30.5
Single agent irinotecan 21.4 25.9
Capecitabine+oxaliplatin 12.1 11.0
FOLFIRI 11.9 7.3
Oxaliplatin+MdG 9.0 6.7
Third-line chemotherapy Unweighted mean
e
(%)
Weighted mean
f
(%)
Mitomycin+5-FU or M+Cap 49.0 44.6
Capecitabine or UFT 11.9 9.2
Capecitabine+irinotecan 7.1 7.0
5-FU regimen 6.7 13.9
Single agent irinotecan 6.5 15.0
Abbreviations: 5-FU¼5-fluorouracil; MdG¼modified de Gramont. Number of
respondents, n.
an¼42.
bn¼41.
cn¼40.
dn¼39.
en¼24.
fn¼23.
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neutropaenia when plotted against the percentage of respondents.
Management of neutropaenia due to irinotecan regimens Twenty-
five experts (57%) stated that they do not treat uncomplicated
neutropaenia, whereas 13 (30%) reported outpatient treatment
and 3 (7%) treated in day case settings. One expert (2%) reported
treating uncomplicated neutropaenia in the inpatient setting. Two
clinicians did not answer this question (5%). For complicated
neutropaenia (neutropaenia of any grade complicated by fever or
infection), 43 clinicians (98%) manage by inpatient treatment. One
clinician (2%) did not answer this question. Mean duration of
inpatient stay due to neutropaenic events was 4.8 days (n¼39,
range 2–10 days, 95% CI 4.3–5.3 days, mean weighted estimate: 5.1
days).
Use of granulocyte colony-stimulating factor Twenty-three
experts (52%) prescribe granulocyte colony-stimulating factor
(G-CSF) in their NHS practice whereas 21 (48%) do not. G-CSF was
most frequently used to treat septic neutropaenia (17 consultants,
39%), followed by its use as secondary prophylaxis (11 consultants,
25%) where G-CSF is administered to prevent neutropaenic events
in patients with previous neutropaenia. Four (9%) consultants
used G-CSF to treat febrile neutropaenia and two (5%) to treat
uncomplicated neutropaenia. None prescribe G-CSF for primary
prophylaxis, where G-CSF is given to prevent neutropaenia in
patients with no previous neutropaenia. Some respondents cited
lack of funding as the reason for not using G-CSF in their NHS
practice, with several reporting prescribing G-CSF only in their
private practice.
Sixteen clinicians prescribe standard formulation multiple-dose
G-CSF, four prescribe single-dose long-acting formulation, two
prescribe both formulations and one did not report formulation
used. Mean duration of G-CSF treatment is 4.4 days (n¼13,
range 3–10 days, 95% CI 3.2–5.5 days, mean weighted estimate:
3.9 days).
Table 3 Frequency of irinotecan-related neutropaenia and diarrhoea estimated by NHS consultant oncologists
Study Experts’ estimates (from survey)
Regimen Second-line IrMdG
Adverse drug events Unweighted Weighted
Mean (%) (s.d.) Median (mode) 95% CI (ranges) Mean (%)
Uncomplicated Neutropaenia 32.9 (17.5) 30 (20) 27.4–38.3 (10.0–80.0) 27.2
Febrile neutropaenia 8.4 (5.3) 5 (5) 6.7–10.0 (2.5–25.0) 7.8
Septic neutropaenia 4.7 (4.3) 4 (5) 3.4–6.0 (0.5–20.0) 3.8
Severe diarrhoea 13.1 (7.7) 10 (10) 10.8–15.5 (1.0–30.0) 12.7
Abbreviation: IrMdG¼irinotecan modified de Gramont.
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Figure 2 Distributions of unweighted estimated frequencies for uncomplicated, febrile and septic neutropaenia and neutropaenic deaths.
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estimated 1 in every 100 patients on irinotecan-based chemother-
apy die because of neutropaenic episodes (n¼24, range 0–10
deaths, 95% CI: 1 death in every 50 patients to 1 death in every
1430 patients, see Figure 2). This estimate for mean number of
neutropaenia-related deaths dropped to 1 death in every 140
patients when estimates are weighted for the number of patients
seen in 2007.
Current use and future preferences for UGT1A1 pharmacogenetic
testing Of the 44 experts, 27% have previously used at least one
pharmacogenetic test (such as KRAS and DPD tests), whereas 68%
had never used a pharmacogenetic test and 5% were uncertain.
None of the experts had used the UGT1A1 pharmacogenetic test.
When asked about future preferences, 23 clinicians (52%)
indicated that if the test were available, they would use UGT1A1
testing to predict risk of irinotecan-related neutropaenia whereas
26 clinicians (59%) would use the test to predict risk of irinotecan-
related diarrhoea.
DISCUSSION
This study identified chemotherapy treatment pathways and
clinical management of NHS advanced CRC patients, frequency
of irinotecan-related neutropaenia and diarrhoea, clinical manage-
ment of irinotecan-related neutropaenia, and current use and
future preferences for UGT1A1 pharmacogenetic testing. Wide
variations in NHS chemotherapy prescribing practice were
identified, which reflect the number of potential combinations
with known active agents and suggest considerable uncertainty
regarding the ideal prescribing regimens and treatment sequence,
corresponding with the small number of clinical trials investigating
use of sequential chemotherapy (Tournigand et al, 2004; Seymour
et al, 2007). A study (Ferro et al, 2008) in the United States, which
used data from a nationwide registry and identified eight
commonly prescribed CRC regimens based on the component
chemotherapy agents, also found variations in the use of CRC
chemotherapy regimens. Ferro et al (2008) shows that the
irinotecan-based regimens used in the United States are not
consistent with the UK-relevant regimens identified in this study.
Despite the lack of standardised patient pathways described in
the literature, this study identified predominant treatment path-
ways within NHS CRC specialties with: first-line treatment with
oxaliplatin-based regimens, second-line treatment with irinotecan-
based regimens and third-line treatment with mitomycin-based
regimens. Current evidence indicate that the use of 5-FU,
oxaliplatin and irinotecan at any sequence within patient’s care
pathway has survival advantages (Grothey et al, 2004). The
predominant treatment pathways showed that NHS clinical
practice reflects the best available evidence on clinical and cost-
effectiveness, despite a paucity of guidelines outlining best practice
and individual clinicians having to rely on their own clinical
experience and personal interpretation of current evidence to
guide practice. It was interesting to note that out of 22 trials
identified that investigated the use of irinotecan with 5-FU, only 1
used IrMdG, the UK-relevant regimen. This implies that clinical
practice within UK CRC specialties is atypical compared to other
countries. It also points to the scarcity of data guiding UK practice.
Data from the sequential trials (Tournigand et al, 2004; Seymour
et al, 2007) revealed that combination irinotecan regimens have
higher frequencies of toxicity in the first-line setting compared to
second-line setting, potentially indicating that only fitter trial
patients received second-line chemotherapy. Comparing the
frequencies of adverse events from the RCTs (Table 1) with NHS
experts’ estimates (Table 3) revealed that irinotecan-related febrile
neutropaenia occurs more frequently within NHS settings. The
frequency of irinotecan-related diarrhoea in the second-line setting
was also higher in NHS practice than in the trials. Differences
between the frequencies of adverse events in NHS practice and the
trials may be due to variations in patient demographics, local clinical
practice or chemotherapy treatment patterns. A National Institute for
Health Clinical Excellence (NICE) health technology assessment
(HTA) (National Institute for Health Clinical Excellence, 2005)
highlighted concern in extrapolating trial data (Tournigand et al,
2004; Seymour et al, 2007) to NHS patients because the trial
populations were relatively young and fit compared to UK CRC
population. This suggests that the safety profile of irinotecan
regimens may be exaggerated as younger and fitter patients may
be less likely to experience clinically significant adverse events, such
as febrile and septic neutropaenia. Furthermore, prescriptive trial
protocols often determine clinical management, such as patient
monitoring, follow-up intervals, prescribing patterns and manage-
ment of ADEs, and do not reflect NHS practice.
Differences around experts’ estimates may reflect their
uncertainty of the true frequencies of ADEs occurring in NHS
practice. Furthermore, differences in the estimates may be a
reflection of variations between institutions and regions, such as
different funding resources, local treatment protocols and
individual clinician’s prescribing preferences. Frequencies of ADEs
reduced when estimates were weighted with number of advanced
CRC patients seen in 2007, potentially indicating that either
clinicians treating many CRC patients are more confident in
irinotecan’s safety profile or increased experience with chemo-
therapy agents leads to reduced adverse events. The clinicians’
low estimate for neutropaenia-related deaths indicated that this is
a rare event. This may suggest that irinotecan-based regimens are
relatively safe and neutropaenic episodes are well managed,
resulting in low mortality rate. However, it may also be influenced
by the nature of NHS patient referral pathways, where patients may
seek treatment for chemotherapy-related complications in a
different NHS institution than where chemotherapy was adminis-
tered. The oncology team administering chemotherapy may not be
aware of patient’s chemotherapy-related morbidity or mortality. A
recent study (National Confidential Enquiry into Patient Outcome
and Death, 2008) found that 15% of cancer patients hospitalised
during their last 30 days of life were not admitted into the same
institution where their systemic chemotherapy was administered.
More than half of the consultants (52%) reported using G-CSF in
their NHS practice. The main indications reported for G-CSF use
were septic neutropaenia and secondary prophylaxis. ASCO
recommends G-CSF as secondary prophylaxis (Smith et al, 2006)
in situations where chemotherapy dose intensity must be
preserved to optimise cytotoxic drugs exposure, implying that
patients with previous neutropaenia are potentially more resource
intensive. Few clinicians used G-CSF to treat febrile neutropaenia,
in line with EORTC (Aapro et al, 2006) and ASCO (Smith et al,
2006) recommendations that G-CSF should only be considered
when patients present septic symptoms. In October 2009, the
Department of Health requested NICE to prepare a clinical
guideline on the prevention and management of neutropaenic
sepsis in cancer patients, underlining the need for clear UK-
relevant recommendations (National Institute of Health and
Clinical Excellence, 2009). This report is yet to be published.
Use of UGT1A1 pharmacogenetic testing in CRC specialties is
currently low, with an increase in demand predicted as many
clinicians indicated they would like to use the test. Pharmacoge-
netic tests will only optimise patients’ outcome if prescribing is
guided by test results. This study did not explore how clinicians
would change their clinical practice based on information from the
UGT1A1 test. Without a regulatory body providing clear
recommendations on how pharmacogenetic test information can
be used to alter clinical pathways, clinicians’ demand for a
pharmacogenetic test may not translate into changes in their
practice or improvement in patient benefits. It is difficult to
predict how CRC oncologists will use UGT1A1 test results in
Chemotherapy treatment pathways for CRC
FH Shabaruddin et al
320
British Journal of Cancer (2010) 103(3), 315–323 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spractice and its subsequent impact on patients’ pathways and
clinical outcome. Wide variations in CRC clinical practice are
potentially associated with variations in the application of
pharmacogenetic testing within the specialty, representing addi-
tional challenges in assessing the added value of a test whose main
objective is to inform and change current prescribing practice.
This offers a further challenge in assessing the added value of such
companion diagnostic tests early in their development.
Limitations
This study used expert opinion in the absence of other data sources.
A detailed retrospective chart review or a large prospective
observational study would be ideal to capture treatment pathways,
clinical management and frequency of adverse events within NHS
CRC specialties. However, there are several challenges to conducting
these types of studies in the United Kingdom. First, the exact
number of CRC consultants in the United Kingdom is not known
and there is no means of identifying these consultants. Second,
patients’ medical records in the United Kingdom are not fully
computerised and data extraction needs to be carried out manually
for each individual patient at the respective health-care institutions
across the country. This means that such a study would require
considerable time, manpower and funding, and the results would
not be timely. Due to barriers to conducting such a costly study, this
pragmatic study was designed.
This study used a postal survey as a systematic method to elicit
expert opinion in a clinical specialty with wide variations in
prescribing practice. Further research is needed to directly
compare this method to other methods that use smaller sample
sizes and are potentially more resource intensive, such as Delphi
methods (Antonini et al, 2008) and methods using specialised
software (Garthwaite et al, 2008). However, consensus-generating
Delphi may introduce additional challenges, as it may not
adequately incorporate uncertainty.
Care must be taken when generalising the results of this survey
to other jurisdictions. The sample size of the expert panel is 44
consultants and potentially represents a good proportion of
eligible consultants in England. The actual number of eligible
consultants is not known as there is no single database of NHS
CRC oncologists. Assuming that all of the 178 NHS Hospital Trusts
have one CRC oncology consultant each, the potential total sample
is 178 consultants. A NICE HTA previously estimated that there
are 12665 advanced CRC patients in England and Wales receiving
chemotherapy annually (National Institute for Health and Clinical
Excellence, 2005). Between the 44 consultants, they treated an
estimated 5940 patients in 2007. Previous elicitation studies that
generated parameter estimates for economic models used smaller
numbers of experts (n¼3 (Garthwaite et al, 2008) and n¼6 (Leal
et al, 2007)) and had identified the experts beforehand. Due to the
study’s main aim to describe CRC clinical practice, with a focus on
irinotecan prescribing practice, the strict inclusion criteria may
have resulted in a small population of interest. Data obtained may
only reflect the views of this specific group of consultants but there
were no systematic differences found between respondents and the
non-respondents contacted in the telephone follow-up.
Implications
Wide variations identified in the chemotherapy pathways of CRC
patients are not uncommon within oncology specialties, and may
occur in other clinical specialties with a fast changing evidence
base. Similar variations exist in the treatment pathway of
chemotherapy-induced neutropaenia. These variations may have
clinical implications on patients’ morbidity and mortality. There is
a need to strike the right balance between allowing clinicians to
decide based on their judgement and having prescriptive clinical
guidelines.
The findings from this study will inform an economic evaluation
of UGT1A1 pharmacogenetic test, which will ensure that the
economic analysis is relevant to UK clinical practice and useful to
NHS decision-makers. Data on the main chemotherapy treatment
pathways for advanced CRC patients will be used to inform
the model structure and the selection of the UK-relevant
irinotecan-based regimen. Data on the management of patients
on irinotecan-based chemotherapy and the clinical management of
irinotecan-related neutropaenia will be used to ensure that the
estimated NHS resource use downstream of the intervention
assessed is relevant to current practice. The ranges and distribu-
tion around the clinicians’ estimates on the frequencies of adverse
events will be used in a probabilistic sensitivity analysis to explore
the impact of the uncertainty around the point estimates.
This study showed the use of critical evidence synthesis and
elicitation of expert opinion to inform the design of an economic
evaluation. The results provide externally valid information and
descriptive empirical evidence upon which to structure the
evaluation. Similar methods can also be used to inform technology
assessments for reimbursement decisions, for example in HTAs
and appraisals of chemotherapy drugs. Current practice in
oncology is often not fully understood because of the rapidly
evolving evidence base and variations in treatment pathways, and
this affects the evaluations in defining the research question, scope
of the evaluation and subsequent analysis, as well as relevance of
results to NHS practice and to decision-makers. For example,
NICE HTA for bevacizumab used irinotecan with bolus 5-FU (IFL
regimen) as the comparator for first-line treatment of advanced
CRC (National Institute of Health and Clinical Excellence, 2006).
Further understanding of NHS clinical practice through this study
has revealed that irinotecan regimens are not relevant comparators
in first-line setting where oxaliplatin-based regimens are the main
chemotherapy of choice; and the IFL regimen is not used in NHS
CRC practice. Selecting a relevant comparator is a key aspect of
ensuring an economic evaluation provides useful information for
decision-making. Inappropriate decisions regarding the choice of
comparator could become a source of uncertainty (Bojke et al,
2009) and can bias the estimated added value of new treatments.
CONCLUSION
This study describes variations in NHS prescribing practice and
clinical management of advanced CRC patients receiving palliative
chemotherapy. Irinotecan-based regimens were primarily used as
second-line chemotherapy. The two main regimens are irinotecan
with infusional 5-FU (IrMdG) and irinotecan monotherapy.
Experts estimated that while uncomplicated neutropaenia is
common, clinically significant neutropaenic events are less
frequent. This method of eliciting expert opinion could potentially
capture heterogeneity in practice and show the complexity of
modelling a standard patient pathway for clinical specialties that
have wide variations in practice with rapidly changing prescribing
and clinical practice.
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